CAR-T cell therapy represents a groundbreaking advance in the treatment of certain blood cancers. This therapy involves modifying a patient’s own T cells to express a chimeric antigen receptor (CAR) that specifically targets cancer cells. CAR-T therapies like tisagenlecleucel and axicabtagene ciloleucel have shown remarkable success in treating refractory or relapsed B-cell lymphomas and leukemias.
